<SEC-DOCUMENT>0001193125-11-355986.txt : 20111230
<SEC-HEADER>0001193125-11-355986.hdr.sgml : 20111230
<ACCEPTANCE-DATETIME>20111230082749
ACCESSION NUMBER:		0001193125-11-355986
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20111230
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20111230
DATE AS OF CHANGE:		20111230

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		111287946

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d275627d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): December&nbsp;30, 2011 (December 30, 2011) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ARCA biopharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 430, Broomfield, CO 80021 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code)
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;8 &#151; Other Events </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01 Other Events. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On December&nbsp;30, 2011, ARCA issued a press release
announcing that the U.S. Patent and Trademark Office has issued a patent on methods for treating patients with bucindolol based on genetic targeting. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by
reference. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;9 &#151; Financial Statements and Exhibits </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:55pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA biopharma Announces Additional Patent Issued for Methods for Treatment with Bucindolol Based on Genetic Targeting,&#148; dated December 30,
2011.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: December&nbsp;30, 2011 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA biopharma, Inc.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(Registrant)</FONT></P></TD></TR>


<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Michael R. Bristow</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: Michael R. Bristow </FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title: &nbsp;&nbsp;President and Chief Executive Officer</FONT></TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>INDEX TO EXHIBITS </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:55pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA biopharma Announces Additional Patent Issued for Methods for Treatment with Bucindolol Based on Genetic Targeting,&#148; dated December 30,
2011.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d275627dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right">


<IMG SRC="g275627g11p18.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Derek Cole </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Investor Relations&nbsp;&amp; Corporate Communications </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">720.940.2163 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">derek.cole@arcabiopharma.com
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA BIOPHARMA ANNOUNCES ADDITIONAL PATENT ISSUED FOR METHODS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FOR TREATMENT WITH BUCINDOLOL BASED ON GENETIC TARGETING </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>------------------------------------------------------------------------ </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Prospective Knowledge of Alpha-2C Genotype May Allow for Prediction of </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Degree of Norepinephrine Lowering by Bucindolol in Individual Patients </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Broomfield, CO, December&nbsp;30, 2011</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced
that the U.S. Patent and Trademark Office (USPTO) has issued a patent on methods for treating patients with bucindolol based on genetic targeting and focused on a specific genotype &#150; homozygous wildtype for Deletion 322-325 in the alpha-2C
adrenergic receptor. The patent (USP# 8,080,578) entitled &#147;Methods for Treatment with Bucindolol Based on Genetic Targeting,&#148; provides protection in the United States for this novel approach to treating patients with bucindolol.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;We are obviously pleased with the USPTO&#146;s issuance of this patent, which we believe extends our pharmacogenetic intellectual
property protection around bucindolol&#148; said Michael R. Bristow, President and Chief Executive Officer of ARCA. &#147;Chronic cardiovascular diseases continue to be a major health care problem, and among the challenges to improving care is the
uncertainty of patient responses to drug treatment. We believe new therapies that include a simple test to identify a substantial subpopulation of patients more likely to benefit have the potential to alleviate some of the problems encountered with
the current standard of pharmacotherapy, where all members of a disease cohort, including those who will not respond, are treated. A unique pharmacologic property of bucindolol is norepinephrine lowering, and bucindolol&#146;s heart failure clinical
responses demonstrated in a large Phase 3 clinical trial (BEST) were modulated by this important effect. The degree of norepinephrine lowering by bucindolol is under genetic control by alpha-2C 322-325 Insertion/Deletion adrenergic receptor
polymorphisms (Circulation Heart Failure: 3:21-28 2010). Accordingly, we believe prospective knowledge of the alpha-2C 322-325 genotype allows for prediction of the degree of norepinephrine lowering by bucindolol in an individual patient.&#148;
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About ARCA biopharma </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT
STYLE="font-family:Times New Roman" SIZE="2">ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company&#146;s lead product candidate, Gencaro</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (bucindolol hydrochloride), is an investigational, pharmacologically
unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations that it believes predict </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
individual patient response to Gencaro, giving it the potential to be the first genetically-targeted atrial fibrillation prevention treatment. ARCA is collaborating with Laboratory Corporation of
America to develop the companion genetic test for Gencaro. For more information please visit www.arcabiopharma.com. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Safe Harbor Statement
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This press release contains &#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities
Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the issuance of, and protection provided by, U.S. Patent 8,080,578 entitled &#147;Methods for Treatment with Bucindolol Based on Genetic
Targeting&#148; and statements regarding the potential for knowledge of the alpha-2C genotype to predict individual patient response to Gencaro; the ability of genetic variations to predict individual patient response to Gencaro; the potential for
Gencaro to be the first genetically-targeted atrial fibrillation prevention treatment; and the Company&#146;s ability to fund future operations. Such statements are based on management&#146;s current expectations and involve risks and uncertainties.
Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company&#146;s financial
resources and whether they will be sufficient to meet the Company&#146;s business objectives and operational requirements; the protection and market exclusivity provided by the Company&#146;s intellectual property; risks related to the drug
discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA&#146;s filings with the SEC, including without limitation
the Company&#146;s annual report on Form 10-K for the year ended December&nbsp;31, 2010 and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g275627g11p18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g275627g11p18.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`,P"8`P$1``(1`0,1`?_$`*<```$$`P$!`0``````
M``````D`!@<(`04*`P0"`0$!``$%`0$!`````````````0(#!@<("04*!!``
M``8!`P0`!0(#!@<``````0(#!`4&!P`1"!(3%`DA,4$B%5$683(CD4(S)!<*
M<:%2DB5%&!$``0,#`P($!`((!P$``````0`"`Q$$!2$Q!D$2(A,'"%%A<3*!
M(Y'!0G*"LA05H?%2,V.S93;_V@`,`P$``A$#$0`_`.B7..<;SG*\RT-%R\A'
MT)G)+QU>KK1P=FT>-VRIVZ<G+@D8GGR$D8HG`%C&31*<I"@&PB;P#]PON%Y]
MZZ\_N\%A[RX@X'%=/ALK*-YBCE9&XL$]SVD>;+,07`2$LC:YK&@'N<[M=Q/B
M>)XIB([JXC8_+.8'22$=Q:2*EK*_:UNQ[=7$5-=`-17L'/'\4\?*(*@O%K)%
M?HG(8%4470BDBL<A@`Q`1>$[1]P#I,H3?YZV]QOV]Y;+X:;(WO>R>U>T3,H0
MYK)#VM<6[CMD'ENJ-"^.NZUK[E\4-PV&,@M>/">A(U(_$:CZ%.FT\?58M6P*
M"B9-"'51;B(AT@=Z])U-4"[;`(@F514WZ$2']0UN[EOMDN<//DYX7/;#8N:S
M6H!EE%8V#^$/D-/V6'XZ_/Q_-A.V%IU=("?X6[G]-!]2HLK]JR;@>P-I>K33
M^)4*=-=Q$K**J1,JS$Q5/&F(HX]A9J[3^1A*58I1`Y#%'I-KB;BO./5CV^<F
MBR7'+VXLKD.#G6[G.-O<QU![+FW)["R0;&C9`*/C<T]KEN.\Q^`Y?9.@OHF2
M-H0'@#O8[:K'C4$?BT[$'4(Z>/;BTR#1JG=V*)FS>SP;"7!J<W69HLY2#RF@
MGV#N>*Z*=/JV#J`N_P!=?H1]->;6?J1P'$<[L&&*VRMA%<>634QN>T%\=>OE
MO[F5H*TK35=2\UC),-EKC%2GN?!*YE?B`=#^(H:=*IXZWNOF(2GM?]C+K@)3
M\*#46L3-7[)&38EQ)0DFV!\"6&Z:^8/\H/$D"+I*-9.6:/&\7'KCN":[LZI0
M,*(ET636U14:W8H6WUV`MM;?HRE=M,)$V.`DVYNIO(PLXP;R<6^0,'P,DZ8N
MB'*/U`VBQVT6NO+2[OJG-M<;SE9K=X6:D"NS=QKDC;:PP>%<H'4/,5V)L-4D
MI-LJT*HF!4I!L8BARGW,!1(8BY\,F>RSV-8NYR5/@2]H_#F>R#>)>F,:SD5O
M$9@C:BO$W1@XDFD[)1"EW<RK`\8U9.0=-""N856XE244*<AQNBS[0145HKT\
M@,F>S?C9BRT9M\+B'R%K>/(5U;+]CZJTW+F*KD6IPR1GMBD*A.R5_O\`%23F
M(BTE'!TG+1,YD4CBF510"IFB@[3IK56!X*<X,8<]<*DRYCIA)5J0BIA6KWVA
MSCAL[F:7:4&C9^+$[YH";:7B)"/>).&+Y,B97*)]C)I*D52(4(H5\'-[GW@[
M@C1XRQ9.7E+)=+<JX8XVQ-3TT7MYODDB*21_":JG*C&0C5TX23</W'],BBI$
MDBK+G(B<@:3LHKQ<I[-\_0C*^7NQ82X35V<;DDZ]BJ-QM(YWS"PBG@=]BGD.
MR6>UU2G04YXQRBJS:1BQT##T*]M4#$`J>T?-0?RZN7MFXBXZL^:,;WKC[RVH
M%)B7<_<JQ.8.FL>Y)@H&/05<R4['LJ?D5:*M,7$MDA5>%0,W>)(%,H1!4I3=
M-5':=]$67%%W1R;BS&F26P-P;Y"Q_3;PB5H)C-2IVNNQTZ4K83'4.*!`?[%W
M,(](?$1'46">C]^QBF+V4DW;=A&QK1S(2+]VJ1!JR8,D#N7CQRLH)4T6[9ND
M8YS&$`*4HB.B(1WK"]EJ?.^[<JJK*(Q,:ICG)"L_A]HS;"S?2N`9E96$K;R4
M(*BGG3<?*PYUGR^Q-@EFZ?2`%`1+)S:(O>BQ0,\-5,LM++"O!R<B11\O_4C$
MU?**!G!_N(!D'#9<-O[IBEW_`.H-?GQ]!^&MSW(9[B[QUU=1_P!0\!T#7>8!
MWG8%KXW_`$+17_4-UVOY7DC;6S6LE8P]@^XBFWU!'U!_!7VDYMM1WE<J;5D1
MS8YZ!74>2=AB3,GC:K*N@9M8Z4BS.%4)-_Y;(_9<',()HIE_F^WI]&,OR&UX
M%>XWAUM`)N4W^-<Z2>]MS%(S'NE$3(;BW+W,GE\V)_E3.)#(V-'B\/;P];VC
M\I%-D7N+;**8!K8W]P,H;W%S'4!:VCA5HW).VM9@79-9-K'I2ZL3(O9-RH[9
MN1CR'!&=4:%;MWKZ,:BDC*G301`B29B[`?;<#!N&N9IK*URUM:QYI]E=7]Y*
MZ2)_D@]EV8@QDLT$?:RX(:T-C8X4#NVH<"0MN-ED@<]UN)&1,:`1W;LK4M:X
MU+*DU)'3X(?6?:/X/G+!#6)=P=155:4G&*K0[A0PB915-FD4X$ZS#ONHLH/\
M`^6O-WW+>GYLH)[QMCDY+X/<YUQ=Q.C<]QJ2\1-!I4ZU?*\_%HV7,7#,L7N:
MSS86QT%&,=6GR+C^IH^I1`N+Y!3X_8K(("`DK)2B`AL("60?AL(#\0$-M>E'
MM*#A[;^(!PHX8EM?KYDBXAY\:\QR!^,Y_E"GD/C]0#^(_(/XB/T`-=BEM!<_
M.1\`J>SC$/L.SLDP)+)61)3"/"ERLW47$M:XLS<A/NK575#$*";;,^;DI1J9
M9/XKQS=`IA$H!JK,>$@*2_0IR9/FWA:UQ7/O%%;SQGG1QT];NC'%^:A29%YG
M'3M<%#"<",&0NX<`V#I_$[?/4*/&M4;O18+DLYIV6N4[_<'\>;3;I^%JM8@V
M^$GLU8['*,82"AV05BYHB\E)>27;1\>U!54I1464(0#&`-_B&BU&_8C.\S^=
M''2.X_Y3H.,<D5+/>9\K8ZNF/L5X<P?.1^5[W<;1<*[(0+#M05&5GG#.$C1D
M!=OGCD$FZ+5$X]8GZ2F+$`[]%#WI0X)Y-X4\>K:MF@J4/DO-EF@[5*49!TW?
MC18&OPIHBO1,N\9J+LE;0\!XX<OB(**)-P420ZS'3..B.()T0M>+3P_/OWJY
M3R5D<?S]0XY.,C2V/:[(B*T;%1>'[(TQOCANV9G,**8-[-,*V)0`#8\F/<-N
M.KT61T;1=<.HM->+ANW>-W#1V@BZ:.T%FSILX3(L@Y;.$S)+H+I*`8BJ*R1Q
M*8H@(&*(@.B+0TZGUC'M3K=%I4(RK=/I\+'5RL5Z,(=..A(*(;)LHR+8)G.H
M9)FQ:)%33+U#TD*`?(-$W5"_8S:9NRTK%_#NB/W;+(7-F_)XD=O8T50D*O@R
M(:A9>1-V(9(0,BG'XX;+1B9Q$-G4NEL.^BR;\?@@V9\C8SUB>Z+#.8Z]'MZE
MQXY0UZ(J-C9,43L:]#,Y5*%QU<6@E(4J*:57LD=7K(H4/Y2+G'ZCJK(>)OS7
M58(;"(?H.HM-`:Q/9(V-F%B/RNEQ"07`K1JL5IW1\@X%*=UVUU"@<?H1,3#]
M#`.OSJ^C'*,3@^336V4\Z3ON']L;'",$EYH#)1[M3T8SN^#@5VXY-C[BXM0Z
M#M'@&I%>@Z:#])5X;568W(S*&F(J?C*==*7#N3K"5)[(5].OKNT#(04\Y,[<
M2*T\I).14340[G9%4R9R&'<">@',N(X[U+LK#.8?)6N#YY@;&0NHV6>R%D^1
MA;9WCS(^9]TZ=Y>Q\/>8G2.B>QQ)$?$^.R$N%DEM;F%]SB[J04U:V3S`#62,
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M[&SM#9>X20TT);VN_&FE1UT:041_B\/5Q]Q48?[U8*;_`+I!\(?\AUZE^TD4
M]MW$!_Y+?^R1<+<^_P#LL@/^<_RA5T]E^<K'A_C+*53&JV^=.2%F@.-6#&:)
M]G@7O++@U?6L*)2'*N1&FUU9[)F6*`E24;I@80Z@UV+6T6BI^07EC#UG<=L7
M8\I./8>:S\W94VN14&7\!R@Y%5.)</&;8@24DSK=;R;&0,*$M*&6='0:-T4"
M*+&Z2@&B%Q.J"%Q^CFGJ_P#=E9,$)J/8S`W*B-8P]-4E7K^0*DUOBJLYCE9>
M5EG*[R2>P&38Z1KIG+A55<Y'HJ*',8PB-61\3:]5UC_+X#]-1::Y.^7S!C*_
M[A_C=&RC%G)1SU/":#QA(-4'K)V@:J783).6CE-5!=,1*`[&*(;@`_,-%J-^
MQ2=[@.%T[QFN=']F7"Z'88XM6+IZ(=9B@Z5$(Q40GT.`:1>2EH*)2;,EXB33
M=&A;8W`A4WK!TFNJ7[72IJC37PE&]X/\P*#S;X_U+-M)%&/D7)0A,ATP7`+/
MZ%D"-10&>K3P?YU&@F5(ZCW`@`.X]PBKL`F,4L6!%"N<C$Y@]:7O(NT5D\?V
MUB+DQ(7MI4KC(?Y:#/6LUV-I<*E(FD7'9:D:U[)$<6!D#F,!6AA[JG2F)3#>
MBU#XFZ+KQ$!`1`0V$-1:2_(B4H"8QBE*4!,8QA`I2E*`B8QC#L!2E`-Q$?@`
M:(H?P9G*A\B:2YR-C)>0DJ2%SO%,A["\:HMF%J5H-HD:A+6.M*(NG7Y"J2$U
M$N`8.S=L72*?<`@%,41*D4W0LL3X[J?L1YA\E^1MR?7@<.<=I!/B3QO?T'(]
MXQLO)35=44FN0-V9V/'5AK<N^935H>,XQ,?(.V<-610,4QDRB6JGPBG50/[C
M/7'CX_#&VY7QDME>8O&#)!G>S%O6:LP97*-!543B\@MXB.R'<K0SB'#:,71E
M%7#5-)8R<7TB82CMJ*M=K3HB0>KCDO\`_57"/#&1)*0"0NM?A?\`3')1S&$[
MC]\X_(C"/GSL3&,;OV**(SE=Q^97P#HHX4*@/.O%#)-)N\M:L6P+^TT^7?+R
MC-K`E\F;KBSQ0RSB,7C"F\Q=JW6.;QW#<JFR0@!^DQ=Q\3O</[./4[A?.[OE
MGI1C[C*\/O+A\\+;0=]U9/E)<^!T%?,?&UQ=Y,L0?1A:U_8YM7=D^)>H>#RN
M*CQV?E9;Y&-@:XR:1R!N@<'?:"13N:ZFM2*@Z,^#:9VC(L\:.+,CE(X636="
M%2G=U?&(<C5,1!G\2)&6.?;Y"80'Z!K8/'[/W)8+$NQ!X?R:2&20.>?[?=>+
ML!$;3^7LTN>[]X@_LA?0O#Q"XN!.,A95`H/SF:5W/W?(#_-.2P/<YR:\T)<6
MY&.E,`7O!^TIT0%5OT*-%P_R?\Z*A!#?Y]!S!]=;HY+D?<?F+B_$7#N3B"]I
MW'^WW7W,H8W_`.WNUPI^ZYXZK^&RM^(V[8JY"R[H]OSH]CN/NZC_`!`3%J_'
M#/.59UHQ?U.;J4."Q0>V"VLEXEG&LS*;K';-7@)/I)<H"(IH(D$HG'[C$`1,
M&P^%^UCW"^K'(H;/+XB_Q.+[OS;S(Q.MXX(B?&8HY>V6=^Y9%&TM+CXG1M+G
M+[-_S?B''K-TMO<17-Q3PQPN#RYU-*EM6M'Q<XUIL"=$:&K59E2J?!T^N]*3
M.MP36&BE'A#+`(LFH(I.GI$E$3*F77#NK`0Q!,)C``A\!#W<X5Q+%<#XCC>&
M80$8G%V45M%7[BV)@;W.Z%[R"YQ&A<25U=R60GRN0FR5U3^HGD<]U-JN-:#Y
M#8?)":R]Z[N6^;^0&'N2=RYPTQG<<`RSB:Q-18/C2L&*JV_?D%&9<N8*4S&_
MF)A_.-!!!R\6>^45)-,$#H"0HZW.OX^X4H!HBQTIK=654A6N0YJM6*[H-#DL
M$Y4*](U2LR+WOK"DXBJY+6&U2,6W!L*93)JR+D14*8P'`#`4I8H*G,7U'9OY
MRY*I^4<O\OZ=4IS'<2I"T9#%7'J1@2PK49LM@2=JRTMF67FWDLVDDDU45N^F
M5N<O4DF03&$Q9]P&P1%\6XVYETC&]@J5WY+8GRS<V\)$1V/<CSN`9F`D&<@T
M<]N2D\CPL!EQ&.NAW<44"I^",*<'6ZJAE0$2:+$D(9E^]/7(7)?*.(YF6/GC
M&-<^5R8K,Q6I*#XUQS2IP/[/;^'`Q#.N.\H/2+PJ3,ZB:Z3A1=1R"ZHJ*"8X
MB!9=P`I31&-I-)O\GC2;HO)&P8ZRZ]L2$U`SSFI8]DZ#5K!39F.)'.(:8JDS
M<[V=1V[16<E<J)O2(*)JE*5$@E$3%C7J$(WC3ZALU\+<FY#NO%CFZ-)I]WE5
M1-BR[X/1R%6'U::/GCFKQ5K5/DB`<R<Y5V;T[9&69?CWATQ.!AZ%#D$LBZHH
M0B%<D>$V)^:6%X#&7*J'A[=:(9D1RUR+0&#ND2]7MB[5-O+3E`_(25H?0<;)
M]L`5C'KF3:+IE*5<JPD(8I8@T.FR@S$G'GV&<:8!CCO'_)K#')#&,"U1C:@E
MR;HMVKV3ZQ#-0[;"%7R+C><E4;6T8-P!)-5]&>0"90*!RD`I"U6K3ONM?G+B
M[[`.5-.EL;Y$Y8XBX[X[L3)>+M4+QLQ7<)VVVB(=%.F]AY#(F0KO&/H^,D$#
MBDNDP8-!62$R:ASIF.0T0%HV%4_$.'.:L9\6L7<3.,7)"!PS4:/C=W09W(TM
MA\UUR=*KOCJJ/K#55T+]6JQ3Y)^K(.UCG,Q?JHKK%.@=,Q"FT2HK4A?)P%X8
M9FX/4F+PNKR`I.6,(1#NU3$?%.\+O:AD9G-V>04F%U"W1GDN8BW\<,NZ764(
M[BUW1BG`A5RE*4`(2#KU5A>4.+,V9GQ]-8UQ1E3'V+(2[U:V4^_2=PQ3(Y/F
M'4/9HTL0):NDE?J=#1*Y(]T[*J9ZVD2',HF)2%Z#`<H"`AG<-O5)R2X&/9T^
M`^<D$_K=M59.;9CO(W'A:=I4Q(1R`-6<PBE&9>B9F'G$V@`@9TT=)"LB4A5B
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M7K-Z@X(BY8O&:I!*JDL1-1,0^X`T4I11A4<[4"XVN=I[*239R<;8Y*MPAWJR
M96]S<PK-!Q,N*RNGU-GR$>LH=(2@H*IQ1.8"]``(E2"!5-S/UNF(1QC"L5ZV
M+U%_<;J4LY))#%I)M:%7F2DQ<I!P]D6ZQXXK=FDFDFJB=(_=7`-Q$0#1`*U4
MRU6XU:\Q0SE0FV,_$@\=L#/&"ACD2?,5.V[9KD4(FL@Y;F$.HARE-L(#\A`=
M$((W7R2E_I4+,Q=<D[/$-K!-2:$-%PH.0<2CJ2<I'72:@R:E771-V$Q.8R@$
M(F3[CB4H@(DH=TI_(%'JTFQAK):X.$E9)H_?LV,B_1;KJL8MLJ\?NS`<>E%N
M@V0.;J4$H'Z!`O4(;:)0K#3(-(?T\N06EHAU:49JN]+9?*`D6+9LLJV7/WE0
M(;K3<H'3$G3UB<HE`!'X:)0UIU6D2S+BI9=%LE?ZR9=>O!:D4_R!`ZX`2-U`
M?@8Q0('V.DA[(CW_`.H7[/B&B4*>-<L<%;X2.L=8E&DW!2R1EHZ38G,HV=ID
M64;J"F)BD.`IKI&(8H@!BF*("&X:*;+5*7ZE)62/IXV>(4M$JL^09039R#N0
M44C&QW<B"J+4JP-"LD""*AEA3*0=BB/4(`)6AWZ)WZ*):(EHB6B):(L&$2E,
M8I.X8I#&*F!@**ABE$Q4P,;8I14,&VX_`-]$5%,?XML%VJ\ZPM51F*]9,GV]
M[8LUV>SQX,724(C.E=LL>4A)90SEXV=L(YJW.\2*5FDW$Y^M1;M$(6=:?J4L
MYLKTY=KCB^F-*8[EZ@5XXLEOF2)HH19VD"Z8KP]+?2RO5^.C)6412=O2$(HJ
MX09$2(0_5L!0:"O5;'*\3+N<D8IL3J"FK+1Z6WN5A4A8"/6E'#G(*;1@TIIG
M+!+["`DV</#-'"PD;-G)0,HHGN4VB#:G5-EF68PC@G)5RNB+-S<K3+VR]24`
MD=)_'HVR\N48^O5!`QNI"1(W5.S:JF*`D54!00W)L.B;F@V38QUBB673X_P9
MXB5A8##:3^ZVJ4FH\\0\L>2Y]@X*O%1;%8A'"S*.DI5XNZ=@7QC@"22)U/N$
ME5)W^:=%EA'SK.*^2;-1;=9(*C,8*C8XBH6+0DB/)R?37G['=W#9=ZU22AXQ
M<C5@5TKN5%P7N;!VRG+%*T%!NO<]<OF)<'VM2KQKR>R;:K-)VJ92KK8DHXC9
MF^V-N,T[A6BHIDDS5&%7V;]0`5=1J!S`!#"`$W.NRTU#K=K>YJ1=2F/I:MT+
M&]<!I0AEUT#BO+VYD#BS7.7DDU7?YV[/$DR,UB)G4!#ON#*+BIOW"$Z?-.EY
MCEU=.0O[PGX(S2GXT@&9:R+E!$K>W7J?23/(V`P``F?-ZQ$LFS5(RH;%<E#H
M_P`/12M&_,K;9TJ\U;:Q`8UJ<,9LA<9\(R<LS-BU*SH=3!NX<6:60W%--O+R
M[!11@TZ"B8RCLX[AL(Z(#K4JN\]C.UQZ%DM]9H4ZR>0)F6$L%UQHP3=/J75'
M#D&=IS`Z9BNF"TK)J*N7#9=8Y5"@5(ZA@Z^HM65>A4\6Z/L>/L/4JG8^JM@3
M3"0JE1EVM.,A+62MU!94XV.68.NID@M-K-$C)G=@)2HNG9E@/]H'&*;G5:#$
MD!;7>6+C9K/0W%0A:I%EQ_C9@H+=.*B*N!VTI)/8M0@JGG9:T28D%VZ)THI$
M:@0%51,&]0THK4ZBQ2T1+1$M$2T1+1$M$2T1+1%5#E-^2\3%OB_G_%_U=QW_
M`(/[3_:'G?N`GC_N/\O_`.7\GIW\/_UWD]OO?=TZ+)O56P'?<=]]_KU=/5O]
A>KI^WJW^>WPW^6BQ6-$2T1+1$M$2T1+1$M$2T1+1%__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
